Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2019
November 12, 2019 at 02:19 pm EST
Share
Sunmax Biotechnology Co., Ltd. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was TWD 189.643 million compared to TWD 77.693 million a year ago. Operating income was TWD 83.170 million compared to TWD 17.090 million a year ago. Net income was TWD 58.801 million compared to TWD 13.723 million a year ago. Basic earnings per share was TWD 1.08 compared to TWD 0.25 a year ago. For the nine months, total revenue was TWD 440.214 million compared to TWD 205.374 million a year ago. Operating income was TWD 152.632 million compared to TWD 35.661 million a year ago. Net income was TWD 114.654 million compared to TWD 44.763 million a year ago. Basic earnings per share was TWD 2.11 compared to TWD 0.83 a year ago. Diluted earnings per share was TWD 2.1 compared to TWD 0.83 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.
SUNMAX BIOTECHNOLOGY CO., LTD. 
